Emma acts for listed and private companies on M&A, equity and debt capital markets, private equity and corporate advisory, with particular expertise in health, life sciences, biotechnology and Asia-Pacific cross-border transactions.

Biography

Emma acts for clients in health, life sciences, biotechnology, technology, agriculture, infrastructure, retail and manufacturing sectors. Her practice includes cross-border transactions with an Asia focus, particularly involving clients in Hong Kong, Singapore, the People's Republic of China and Indonesia.

Emma advises on equity and debt capital markets, mergers and acquisitions, private equity and corporate advisory. She provides clients with access to high-level skills in areas that are heavily regulated and highly technical, spanning the full transaction lifecycle from structuring through to execution and governance.

Emma has advised Microba Life Sciences on its ASX listing, raising A$30 million (reflected in a client testimonial from CEO Luke Reid describing the team as the most pragmatic legal firm he has worked with over his career). She has also acted on the QBiotics Group A$130 million merger via dual schemes of arrangement consolidating QBiotics Limited and EcoBiotics Limited, and on the Cronos Australia merger with CDA Health. Her practice spans the full range of capital markets and M&A complexity in highly regulated sectors including life sciences and biotechnology.

Emma's combination of technical capital markets expertise with deep sector knowledge in health and life sciences, and her cross-border Asia-Pacific capability, positions her as a specialist in regulated sector transactions.

Emma's experience

Microba Life Sciences — ASX listing and A$30 million IPO

Advising Microba Life Sciences on its ASX listing, including transaction structuring, regulatory compliance and delivering an IPO raising A$30 million.

QBiotics Group — A$130 million dual scheme merger

Advising on the A$130 million merger via dual schemes of arrangement consolidating QBiotics Limited and EcoBiotics Limited into QBiotics Group Ltd.

Cronos Australia — Merger with CDA Health

Advising Cronos Australia on its merger with CDA Health, a major medicinal cannabis distributor.

Cross-border Asia-Pacific transactions

Advising on capital markets and M&A transactions involving clients in Hong Kong, Singapore, the People's Republic of China and Indonesia across health, life sciences and technology sectors.

Awards, recognition and ranking